Zachman Angela L, Wang Xintong, Tucker-Schwartz Jason M, Fitzpatrick Sean T, Lee Sue H, Guelcher Scott A, Skala Melissa C, Sung Hak-Joon
Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Biomaterials. 2014 Dec;35(36):9635-48. doi: 10.1016/j.biomaterials.2014.08.011. Epub 2014 Aug 22.
Peripheral artery disease (PAD) is characterized by vessel occlusion and ischemia in the limbs. Treatment for PAD with surgical interventions has been showing limited success. Moreover, recent clinical trials with treatment of angiogenic growth factors proved ineffective as increased angiogenesis triggered severe inflammation in a proportionally coupled fashion. Hence, the overarching goal of this research was to address this issue by developing a biomaterial system that enables controlled, dual delivery of pro-angiogenic C16 and anti-inflammatory Ac-SDKP peptides in a minimally-invasive way. To achieve the goal, a peptide-loaded injectable microgel system was developed and tested in a mouse model of PAD. When delivered through multiple, low volume injections, the combination of C16 and Ac-SDKP peptides promoted angiogenesis, muscle regeneration, and perfusion recovery, while minimizing detrimental inflammation. Additionally, this peptide combination regulated inflammatory TNF-α pathways independently of MMP-9 mediated pathways of angiogenesis in vitro, suggesting a potential mechanism by which angiogenic and inflammatory responses can be uncoupled in the context of PAD. This study demonstrates a translatable potential of the dual peptide-loaded injectable microgel system for PAD treatment.
外周动脉疾病(PAD)的特征是肢体血管闭塞和缺血。手术干预治疗PAD的成功率一直有限。此外,最近关于血管生成生长因子治疗的临床试验证明无效,因为增加的血管生成以比例耦合的方式引发了严重炎症。因此,本研究的总体目标是通过开发一种生物材料系统来解决这个问题,该系统能够以微创方式实现促血管生成C16肽和抗炎Ac-SDKP肽的可控双递送。为了实现这一目标,开发了一种负载肽的可注射微凝胶系统,并在PAD小鼠模型中进行了测试。当通过多次小剂量注射给药时,C16肽和Ac-SDKP肽的组合促进了血管生成、肌肉再生和灌注恢复,同时将有害炎症降至最低。此外,这种肽组合在体外独立于MMP-9介导的血管生成途径调节炎症TNF-α途径,这表明在PAD背景下血管生成和炎症反应可以解耦的潜在机制。这项研究证明了负载双肽的可注射微凝胶系统在PAD治疗中的可转化潜力。